A wide scan of plasma proteins demonstrates thioredoxin reductase 1 as a potential new diagnostic biomarker for hepatocellular carcinoma

References

• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650–2666.
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462.
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening Is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol: 2019;17(5):976–987 e4.
   PubMed Web of Science ®Google Scholar
• Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–139.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718 e1.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94(8):2224–2229.
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229.
   PubMed Web of Science ®Google Scholar
• Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139(1):46–50.
   PubMed Web of Science ®Google Scholar
• Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis. Medicine. 2021;100(43):e27673.
   PubMed Web of Science ®Google Scholar
• Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine. 2017;96(11):e5811.
   PubMed Web of Science ®Google Scholar
• Fang YS, Wu Q, Zhao HC, et al. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(9):1065–1076.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao J, Bao Y, et al. Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a meta-analysis. Biomarkers. 2022;27(1):13–21.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Yeon JE, Suh SJ, et al. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8(2):177–185.
   PubMed Web of Science ®Google Scholar
• Sun T, Tang Y, Sun D, et al. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. OTT. 2018 11:8925–8935.
   Web of Science ®Google Scholar
• Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59(12):1687–1693.
   PubMed Web of Science ®Google Scholar
• Ozkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of golgi protein 73 in hepatocellular carcinoma. Digestion. 2011;83(1–2):83–88.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang H, Xu H, et al. Golgi protein 73, not glypican-3, may be a tumor marker complementary to alpha-Fetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol. 2014;29(3):597–602.
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif. 2019;52(2):e12538.
   PubMed Web of Science ®Google Scholar
• Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125(1):89–97.
   PubMed Web of Science ®Google Scholar
• Jiang D, Zhang Y, Wang Y, et al. Diagnostic accuracy and prognostic significance of glypican-3 in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:1012418.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–118.
   PubMed Web of Science ®Google Scholar
• Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493–502.
   PubMed Web of Science ®Google Scholar
• Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie. 2016;54(12):1296–1305.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer epidemiology, biomarkers & prevention: a publication of the American association for cancer research, cosponsored by the.ASPO. 2014;23(1):144–153.
   Google Scholar
• Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer epidemiology, biomarkers & prevention: a publication of the American association for cancer research, cosponsored by the.ASPO. 2019;28(3):531–538.
   Google Scholar
• Biselli M, Conti F, Gramenzi A, et al. A new approach to the use of alpha-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer. 2015;112(1):69–76.
   PubMed Web of Science ®Google Scholar
• Suhre K, McCarthy MI, Schwenk JM. Genetics meets proteomics: perspectives for large population-based studies. Nat Rev Genet. 2021;22(1):19–37.
   PubMed Web of Science ®Google Scholar
• Deutsch EW, Omenn GS, Sun Z, et al. Advances and utility of the human plasma proteome. J Proteome Res. 2021;20(12):5241–5263.
   PubMed Web of Science ®Google Scholar
• Correa Rojo A, Heylen D, Aerts J, et al. Towards building a quantitative proteomics toolbox in precision medicine: a mini-review. Front Physiol. 2021;12:723510.
   PubMed Web of Science ®Google Scholar
• Schwenk JM, Igel U, Neiman M, et al. Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol Cell Proteomics. 2010;9(11):2497–2507.
   PubMed Web of Science ®Google Scholar
• Dodig-Crnković T, Hong MG, Thomas CE, et al. Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling. EBioMedicine. 2020;57:102854.
   PubMed Web of Science ®Google Scholar
• Astrom E, Stal P, Zenlander R, et al. Reverse lectin ELISA for detecting fucosylated forms of alpha1-acid glycoprotein associated with hepatocellular carcinoma. PLOS One. 2017;12(3):e0173897.
   PubMed Web of Science ®Google Scholar
• Nguyen P, Awwad RT, Smart DD, et al. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Letters. 2006;236(2):164–174.
   PubMed Web of Science ®Google Scholar
• Fernandes AP, Capitanio A, Selenius M, et al. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology. 2009;55(3):313–320.
   PubMed Web of Science ®Google Scholar
• Cañas A, López-Sánchez LM, Valverde-Estepa A, et al. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. Breast Cancer Res. 2012;14(6):R153.
   PubMed Web of Science ®Google Scholar
• Esen H, Erdi F, Kaya B, et al. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. J Neurooncol. 2015;121(3):451–458.
   PubMed Web of Science ®Google Scholar
• Fu B, Meng W, Zeng X, et al. TXNRD1 Is an unfavorable prognostic factor for patients with hepatocellular carcinoma. Biomed Res Int. 2017;2017:1–8.
   Web of Science ®Google Scholar
• Tucker B, Li H, Long X, et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metab clin Exp. 2019;101:153994.
   PubMed Web of Science ®Google Scholar
• Singhal G, Kumar G, Chan S, et al. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab. 2018;13:56–66.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li Y, Liang T, et al. Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation. Am J Cancer Res. 2015;5(5):1762–1774.
   PubMed Web of Science ®Google Scholar
• Liu ZY, Luo Y, Fang AP, et al. High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: a prospective cohort study. Liver Int. 2022;42(3):663–673.
   PubMed Web of Science ®Google Scholar
• Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212–220.
   PubMed Web of Science ®Google Scholar
• Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients. WJG. 2020;26(34):5130–5145.
   PubMed Web of Science ®Google Scholar
• Tanabe K, Kitagawa K, Kojima N, et al. Multifucosylated alpha-1-acid glycoprotein as a novel marker for hepatocellular carcinoma. J Proteome Res. 2016;15(9):2935–2944.
   PubMed Web of Science ®Google Scholar